Your browser doesn't support javascript.
loading
Derivation of a score to predict infection due to multidrug-resistant Pseudomonas aeruginosa: a tool for guiding empirical antibiotic treatment.
Hernández-Jiménez, Pilar; López-Medrano, Francisco; Fernández-Ruiz, Mario; Silva, Jose T; Corbella, Laura; San-Juan, Rafael; Ruiz-Ruigómez, María; Lizasoain, Manuel; Rodríguez-Goncer, Isabel; Díaz-Regañón, Jazmín; López-Mendoza, Diego; Viedma, Esther; Aguado, José María.
Afiliação
  • Hernández-Jiménez P; Unit of Infectious Diseases, Hospital Universitario, Instituto de Investigación Sanitaria Hospital, Madrid, Spain; Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain. Electronic address: pilihj@hotmail.com.
  • López-Medrano F; Unit of Infectious Diseases, Hospital Universitario, Instituto de Investigación Sanitaria Hospital, Madrid, Spain; Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud
  • Fernández-Ruiz M; Unit of Infectious Diseases, Hospital Universitario, Instituto de Investigación Sanitaria Hospital, Madrid, Spain; Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud
  • Silva JT; Unit of Infectious Diseases, Hospital Universitario, Instituto de Investigación Sanitaria Hospital, Madrid, Spain.
  • Corbella L; Unit of Infectious Diseases, Hospital Universitario, Instituto de Investigación Sanitaria Hospital, Madrid, Spain.
  • San-Juan R; Unit of Infectious Diseases, Hospital Universitario, Instituto de Investigación Sanitaria Hospital, Madrid, Spain; Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud
  • Ruiz-Ruigómez M; Unit of Infectious Diseases, Hospital Universitario, Instituto de Investigación Sanitaria Hospital, Madrid, Spain.
  • Lizasoain M; Unit of Infectious Diseases, Hospital Universitario, Instituto de Investigación Sanitaria Hospital, Madrid, Spain; Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain.
  • Rodríguez-Goncer I; Unit of Infectious Diseases, Hospital Universitario, Instituto de Investigación Sanitaria Hospital, Madrid, Spain.
  • Díaz-Regañón J; Medical Department of Merck Sharp & Dohme Española S.A., Madrid, Spain.
  • López-Mendoza D; Medical Department of Merck Sharp & Dohme Española S.A., Madrid, Spain.
  • Viedma E; Department of Microbiology, Hospital Universitario, Instituto de Investigación Sanitaria Hospital, Madrid, Spain.
  • Aguado JM; Unit of Infectious Diseases, Hospital Universitario, Instituto de Investigación Sanitaria Hospital, Madrid, Spain; Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud
J Glob Antimicrob Resist ; 29: 215-221, 2022 06.
Article em En | MEDLINE | ID: mdl-35339736
ABSTRACT

OBJECTIVES:

Multidrug-resistant Pseudomonas aeruginosa (MDR-PSA) constitutes an emerging health problem. A predictive score of MDR-PSA infection would allow an early adaptation of empirical antibiotic therapy.

METHODS:

We performed a single-centre case-control (12) retrospective study including 100 patients with MDR-PSA and 200 with a non-MDR-PSA infection. Cases and controls were matched by site of infection, clinical characteristics and immunosuppression. A point risk score for prediction of MDR-PSA infection was derived from a logistic regression model. Secondary outcomes (clinical improvement, complications and discharge) were also compared.

RESULTS:

Cases with MDR-PSA infection were younger than controls (67.5 vs. 73.0 y; P = 0.031) and have more frequent cirrhosis (9% vs. 2%; P = 0.005). Independent risk factors for MDR-PSA infection were prior antibiotic treatment (80% vs. 50.5%; P < 0.001), prior colonisation with MDR bacteria (41% vs. 13.5%; P < 0.001), hospital-acquired infection (63% vs. 47%; P = 0.009) and septic shock at diagnosis (33% vs. 14%; P < 0.001). Adequate therapy was less frequent in MDR-PSA infections (31% vs. 66.5% for empirical therapy; P < 0.001). The risk score included previous MDR-PSA isolation (11 points), prior antibiotic use (3 points), hospital-acquired infection (2 points) and septic shock at diagnosis (2 points). It showed an area under the curve of 0.755 (95% CI 0.70-0.81) and allowed to classify individual risk into various categories 0-2 points (<20%), 3-5 points (25%-45%), 7-11 points (55%-60%), 13-16 points (75%-87%) and a maximum of 18 points (93%).

CONCLUSION:

Infections due to MDR-PSA have a poorer prognosis than those produced by non-MDR-PSA. Our score could guide empirical therapy for MDR-PSA when P. aeruginosa is isolated.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por Pseudomonas / Choque Séptico / Infecção Hospitalar / Farmacorresistência Bacteriana Múltipla Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Glob Antimicrob Resist Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por Pseudomonas / Choque Séptico / Infecção Hospitalar / Farmacorresistência Bacteriana Múltipla Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Glob Antimicrob Resist Ano de publicação: 2022 Tipo de documento: Article